Deutsche Bank downgraded DocGo (DCGO) to Hold from Buy with a price target of $2.85, down from $5. The firm reduced reduced 2025 EBITDA estimates due to DocGo deciding to invest in its transition to care gap closure. Given concerns from a lack of visibility, the analyst feels a nearer-term multiple is more appropriate for shares. The potential upside in offset by the company’s significant execution risks around shifting to the base business and margins, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DCGO:
- DocGo price target lowered to $5.50 from $6.50 at Stifel
- DocGo’s Strategic Shift Towards Sustainable Growth: Analyst Recommends Buy Despite Current Challenges
- DocGo’s Strategic Shift and Growth Potential Justify Buy Rating Despite Short-Term Challenges
- Optimistic Buy Rating for DocGo Amid Strategic Transition and Growth Potential
- DocGo Inc. Reports Mixed 2024 Financial Results
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue